抗发作药物使良性症儿童的脑电图功能连接和功率正常化 带有中点的中心点
Min-Lan Tsai1, Chuang-Chin Wang2, Andy Yu-Der Wang3
1Division of Pediatric Neurology, Department of Pediatrics, Taipei Medical University Hospital, Taipei Medical University, Taipei, Taiwan; Department of Pediatrics, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
抗发作药物 (ASM) 在患有带有中点 (BECTS) 的良性的儿童中没有改变EEG连接性. ASM治疗确实使慢波频段功率正常化,这表明它在调节大脑连接发展中的作用.
科学领域:
- 神经科学是一个神经科学.
- 的研究研究.
- 儿科神经学 儿科神经学
背景情况:
- 在儿童中使用抗药物 (ASM) 治疗良性与中尖峰 (BECTS) 仍然是争论的主题.
- 了解ASM对大脑活动的影响对于治疗决策至关重要.
研究的目的:
- 为了比较ASM治疗与非ASM治疗对BECTS儿童脑电图 (EEG) 功能连接和功率的影响.
- 在两年内调查四个频段的EEG网络属性和功率的变化.
主要方法:
- 对患有BECTS的儿童的EEG数据的回顾性分析,分为ASM和非ASM组,随访两年.
- 评估EEG网络属性 (全球效率,集群系数,中间中心性,节点强度) 和功率 (绝对和相对) 在三角形,三角形,α和β频段.
主要成果:
- 在BECTS患者的ASM治疗中,两年来所有频段的EEG连接性没有显著变化.
- 没有接受ASM的BECTS儿童在三角波段的全球效率,聚类系数和节点强度显著增加.
- 两年后,ASM组在delta和theta频段的绝对功率和theta频段的相对功率下降.
结论:
- ASM可能会影响整体大脑连接的发展,并减少早期BECTS的突触活动,而不会影响内在的焦点连接.
- 脑电图功率分析表明,ASM在患有BECTS的儿童中显著使慢波频段功率正常化.
更多相关视频
09:57Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
09:00Investigating the Function of Deep Cortical and Subcortical Structures Using Stereotactic Electroencephalography: Lessons from the Anterior Cingulate Cortex
Published on: April 15, 2015
相关概念视频
Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Arteries of the Lower Limbs
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
